

CLR_16_31

CLINICAL DEVELOPMENT OF [REDACTED]

Clinical Trial Protocol: CLR_16_31

Protocol Title: A Randomized, Double-Masked, Parallel Group, Multicenter, Study To Evaluate Efficacy And Safety of SPARC's SDN-037 Twice Daily Compared With Vehicle For The Treatment Of Inflammation And Pain Associated With Ocular Surgery.

Protocol Number CLR_16_31

Version No. 01

Amendment No. Amendment 02

Date 02 Aug 2019

Study Phase: 3

Investigational Product Name: [REDACTED]

IND Number: [REDACTED]


Indication: Inflammation and pain associated with ocular surgery

Investigators: Multi-center

Sponsor: Sun Pharma Advanced Research Company, Ltd. (SPARC)
17 B Mahal Industrial Estate,
Mahakali Caves Rd Andheri (E),
Mumbai - 400 093
India

CLR_16_31

SPONSOR APPROVAL SIGNATURE



Sponsor's Medical Expert for the Study

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]







[REDACTED]

[REDACTED]

[REDACTED]

1.0 SYNOPSIS

Title of the Study	A Randomized, Double-Masked, Parallel Group, Multicenter, Study To Evaluate Efficacy And Safety of SPARC's SDN - 037 Twice Daily Compared With Vehicle For The Treatment Of Inflammation And Pain Associated With Ocular Surgery.
Protocol Number	CLR_16_31
Investigational Product:	[REDACTED]
Study Phase:	3
Primary Objective(s):	To evaluate the efficacy and safety of topical administration of [REDACTED] compared with [REDACTED] when dosed [REDACTED] post cataract surgery.
Secondary Objective(s):	N/A
Overall Study Design Structure	Multi-center, double-masked, parallel group, randomization.
Duration:	Total duration: [REDACTED]
Vehicle:	Vehicle of [REDACTED]
Estimated Duration of Trial	Approximately [REDACTED]
Dosage/Dose Regimen/ Instillation/Application/Use:	1 drop of either: [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
Summary of Visit	[REDACTED]

	                                                                               
Evaluation Criteria :	<p>Primary Efficacy Endpoint The primary efficacy endpoint is the proportion of subjects with an anterior chamber cell (ACC) grade of 0 at Day 15</p> <p>Secondary Efficacy Endpoint The key secondary efficacy endpoint is the proportion of subjects who achieve a pain score of 0 at day 15</p>
Safety Measures:	                 
Efficacy Analysis:	                 

	[REDACTED]
Safety Analyses:	[REDACTED]
	[REDACTED]
	[REDACTED]

TABLE OF CONTENTS

1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100
101	101
102	102
103	103
104	104
105	105
106	106
107	107
108	108
109	109
110	110
111	111
112	112
113	113
114	114
115	115
116	116
117	117
118	118
119	119
120	120
121	121
122	122
123	123
124	124
125	125
126	126
127	127
128	128
129	129
130	130
131	131
132	132
133	133
134	134
135	135
136	136
137	137
138	138
139	139
140	140
141	141
142	142
143	143
144	144
145	145
146	146
147	147
148	148
149	149
150	150
151	151
152	152
153	153
154	154
155	155
156	156
157	157
158	158
159	159
160	160
161	161
162	162
163	163
164	164
165	165
166	166
167	167
168	168
169	169
170	170
171	171
172	172
173	173
174	174
175	175
176	176
177	177
178	178
179	179
180	180
181	181
182	182
183	183
184	184
185	185
186	186
187	187
188	188
189	189
190	190
191	191
192	192
193	193
194	194
195	195
196	196
197	197
198	198
199	199
200	200
201	201
202	202
203	203
204	204
205	205
206	206
207	207
208	208
209	209
210	210
211	211
212	212
213	213
214	214
215	215
216	216
217	217
218	218
219	219
220	220
221	221
222	222
223	223
224	224
225	225
226	226
227	227
228	228
229	229
230	230
231	231
232	232
233	233
234	234
235	235
236	236
237	237
238	238
239	239
240	240
241	241
242	242
243	243
244	244
245	245
246	246
247	247
248	248
249	249
250	250
251	251
252	252
253	253
254	254
255	255
256	256
257	257
258	258
259	259
260	260
261	261
262	262
263	263
264	264
265	265
266	266
267	267
268	268
269	269
270	270
271	271
272	272
273	273
274	274
275	275
276	276
277	277
278	278
279	279
280	280
281	281
282	282
283	283
284	284
285	285
286	286
287	287
288	288
289	289
290	290
291	291
292	292
293	293
294	294
295	295
296	296
297	297
298	298
299	299
300	300
301	301
302	302
303	303
304	304
305	305
306	306
307	307
308	308
309	309
310	310
311	311
312	312
313	313
314	314
315	315
316	316
317	317
318	318
319	319
320	320
321	321
322	322
323	323
324	324
325	325
326	326
327	327
328	328
329	329
330	330
331	331
332	332
333	333
334	334
335	335
336	336
337	337
338	338
339	339
340	340
341	341
342	342
343	343
344	344
345	345
346	346
347	347
348	348
349	349
350	350
351	351
352	352
353	353
354	354
355	355
356	356
357	357
358	358
359	359
360	360
361	361
362	362
363	363
364	364
365	365
366	366
367	367
368	368
369	369
370	370
371	371
372	372
373	373
374	374
375	375
376	376
377	377
378	378
379	379
380	380
381	381
382	382
383	383
384	384
385	385
386	386
387	387
388	388
389	389
390	390
391	391
392	392
393	393
394	394
395	395
396	396
397	397
398	398
399	399
400	400
401	401
402	402
403	403
404	404
405	405
406	406
407	407
408	408
409	409
410	410
411	411
412	412
413	413
414	414
415	415
416	416
417	417
418	418
419	419
420	420
421	421
422	422
423	423
424	424
425	425
426	426
427	427
428	428
429	429
430	430
431	431
432	432
433	433
434	434
435	435
436	436
437	437
438	438
439	439
440	440
441	441
442	442
443	443
444	444
445	445
446	446
447	447
448	448
449	449
450	450
451	451
452	452
453	453
454	454
455	455
456	456
457	457
458	458
459	459
460	460
461	461
462	462
463	463
464	464
465	465
466	466
467	467
468	468
469	469
470	470
471	471
472	472
473	473
474	474
475	475
476	476
477	477
478	478
479	479
480	480
481	481
482	482
483	483
484	484
485	485
486	486
487	487
488	488
489	489
490	490
491	491
492	492
493	493
494	494
495	495
496	496
497	497
498	498
499	499
500	500
501	501
502	502
503	503
504	504
505	505
506	506
507	507
508	508
509	509
510	510
511	511
512	512
513	513
514	514
515	515
516	516
517	517
518	518
519	519
520	520
521	521
522	522
523	523
524	524
525	525
526	526
527	527
528	528
529	529
530	530
531	531
532	532
533	533
534	534
535	535
536	536
537	537
538	538
539	539
540	540
541	541
542	542
543	543
544	544
545	545
546	546
547	547
548	548
549	549
550	550
551	551
552	552
553	553
554	554
555	555
556	556
557	557
558	558
559	559
560	560
561	561
562	562
563	563
564	564
565	565
566	566
567	567
568	568
569	569
570	570
571	571
572	572
573</	

This figure is a 2D bar chart consisting of 100 horizontal bars. The bars are black and are arranged in a single row. The length of each bar represents a data value. There is a clear, gradual decrease in the length of the bars from left to right, creating a visual gradient. The first 10 bars on the left are the longest, followed by a series of 80 bars of decreasing length, and finally the last 10 bars on the right are the shortest.

Category	Value
0	100
1	95
2	85
3	85
4	85
5	85
6	85
7	85
8	85
9	85
10	85
11	85
12	75
13	75
14	75
15	75
16	75
17	75
18	75
19	75

A horizontal bar chart with six data series. The first series is a short black bar. The second series is a long black bar. The third series is a very long black bar. The fourth series is a medium-length black bar. The fifth series is a short black bar. The sixth series is a very long black bar.

LIST OF ABBREVIATIONS

ACC	Anterior Chamber Cell
ACF	Anterior Chamber Flare
AE	Adverse Event
BCVA	Best Corrected Visual Acuity
BID	Twice a day (<i>bis in die</i>)
BSCVA	Best-Spectacle Corrected Visual Acuity
CI	Confidence Interval
CRO	Contract Research Organization
eCRF	electronic Case Report Form
ETDRS	Early Treatment Diabetic Retinopathy Study
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
IEC	Independent Ethics Committee
IND	Investigational New Drug
IOP	Intraocular Pressure
IOL	Intra Ocular Lens
IP	Investigational Product
IRB	Institutional Review Board
IWRS	Interactive Web Response System
mITT	Modified Intent-To-Treat
LAR	Legally Acceptable Representative
LOCF	Last Observation Carried Forward
logMAR	Logarithm of the Minimum Angle of Resolution
MedDRA	Medical Dictionary of Regulatory Affairs

MRHD	Maximum Recommended Human Dose
NDA	New Drug Application
NOAEL	No Observed Adverse Effect Level
OPD	(in-)Office Physician Dispensing
PP	Per Protocol
PT	Preferred Term
RLD	Reference Listed Drug
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SOC	System Organ Class
SPARC	Sun Pharma Advanced Research Company, Ltd.
SUSAR	Suspected Unexpected Serious Adverse Reaction
TEAE	Treatment-Emergent Adverse Event
VAS	Visual analog scale
WHO-DD	World Health Organisation Drug Dictionary

2.0 BACKGROUND INFORMATION

Surgical technique in all fields of ophthalmology has evolved considerably over the years, from the transition to clear corneal incisions by anterior segment surgeons to the adoption of small-gauge minimally invasive pars plana vitrectomies by vitreoretinal specialists. Despite such technical advances, however, surgical manipulation of anterior segment structures triggers the release of arachidonic acid from cell membranes, leading to the production of prostaglandins and leukotrienes. These inflammatory mediators, in turn, lead to cellular reaction and protein leakage. Untreated inflammation can lead to complications such as pain/discomfort, photophobia, corneal edema, synechiae, glaucoma, and cystoid macular edema.■

In the immediate postoperative period, topical corticosteroids are employed to suppress the production of inflammatory mediators. By inhibiting the release of arachidonic acid from cell membrane phospholipids, corticosteroids prevent the formation of both leukotrienes and prostaglandins, disrupting the inflammatory cascade.■ These agents are continued until the anterior chamber (AC) reaction has resolved and the blood–aqueous barrier has been reestablished.■

In June 2008, difluprednate ophthalmic emulsion 0.05% (DurezolTM; Sirion Therapeutics, Tampa, FL) was approved by the US Food and Drug Administration (FDA) for the treatment of inflammation and pain associated with ocular surgery.

Sun Pharma Advanced Research Company Ltd. (SPARC) has developed a novel topical ophthalmic formulation of ■■■■■ for the treatment of inflammation and pain associated with ocular surgery. SPARC intends to develop the ophthalmic ■■■■■ product at a ■■■ dose ■■■■■ and with a ■■■■■ frequency, ■■■■■ compared to ■■■■■

2.1 Summary of Findings from Nonclinical Studies

Safety and efficacy of Durezol ■■■■■ were extensively and adequately evaluated in nonclinical studies as described in Prescribing Information and Product Monograph.■ The pharmacology studies in animal models of uveitis demonstrated that ■■■■■ ■■■■■ was effective in a dose-dependent manner. SPARC plans to seek approval of ■■■■■ for the same indications as those for Durezol, and thus use Durezol as the reference listed drug (RLD). To support development of the novel ophthalmic formulation of ■■■■■ ■■■■■

■■■■■ ■■■■■ ■■■■■

2.1.1 Pharmacology

In the [REDACTED] model, [REDACTED] significantly reduced total clinical score, total cell count and total protein levels in aqueous humor compared to the disease control. [REDACTED] administration of [REDACTED] demonstrated comparable, significant effects on all these measurements, whereas [REDACTED] [REDACTED] only had a significant effect on reducing total clinical score, but not on total cell count or total protein levels in aqueous humor.

In the [REDACTED] model, [REDACTED] [REDACTED] treatment demonstrated comparable efficacy as [REDACTED] ocular instillation. Both treatments significantly reduced total clinical score, total cell count and total protein levels in aqueous humor. [REDACTED] dosed at a [REDACTED] dose of [REDACTED] had no significant effect on these measurements as compared to [REDACTED].

2.1.2 Pharmacokinetics:

Pharmacokinetic profile of Durezol, 0.05% w/v, is well established by ocular route. The systemic absorption of ocular administered difluprednate is very small. During the 7 days ocular instillation studies in rabbits of 0.05% 3 H-difluprednate, the Cmax in the plasma was not more than 10 ng/g dry weight. Difluprednate is rapidly metabolized by deacetylation (at 21- position) in the rabbit eye tissues to the metabolite 6 alpha-9-difluoroprednisolone 17- butyrate, active metabolite (DFB), which is in turn converted to 17-debutyloylated DFB , a breakdown product of DFB. Single-dose and multiple-dose studies of difluprednate in rabbits demonstrate that difluprednate is rapidly metabolized and distributed to the main ocular target tissues that are affected by inflammation (iris, ciliary body, choroids, and aqueous humor in the anterior chamber), difluprednate does not accumulate in the blood, and difluprednate seems to have a low affinity for melanin, which indicates that difluprednate should work effectively in patients regardless of their race and eye color (i.e., differing levels of melanin in the eye, brown eyes having higher levels of melanin than blue eyes). Single-dose studies also showed 99.5% of difluprednate and its metabolites were cumulatively excreted via the feces and urine, and after repeated doses, difluprednate levels increased without affecting the Cmax, with clearance from most ocular tissues within 168 hours

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED]

2.1.3 Toxicology

[REDACTED]
[REDACTED]
[REDACTED] . The NOAELs in the [REDACTED] were [REDACTED]
[REDACTED] . Neither deaths nor serious toxicological findings were noted in the studies. Many changes at higher doses were those generally observed in glucocorticoid (GC) treated animals. Ocular

[REDACTED] [REDACTED] [REDACTED]

administration of [REDACTED] for up to [REDACTED]

[REDACTED] difluprednate and difluprednate metabolites were negative. Reproductive toxicity tests were performed with difluprednate in rats and rabbits. Fetal death and malformations such as cleft palate (commonly associated with high-dose administration of GCs) were observed during the organogenesis in rabbits. The effects of difluprednate on rat fetuses were weak; fetal death and/or malformed fetuses were not found. Long-term studies have not been conducted to evaluate the carcinogenic potential of difluprednate. [REDACTED]

© 2013 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

Digitized by srujanika@gmail.com

© 2013 Pearson Education, Inc.

1000

© 2013 Pearson Education, Inc. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s). Editorial review has determined that any suppressed content does not materially affect the overall learning experience. Pearson Education, Inc. reserves the right to remove additional content at any time if subsequent rights restrictions require it.

© 2019 Pearson Education, Inc.

© 2019 Pearson Education, Inc.

© 2019 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

© 2019 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

10 of 10

11. *What is the primary purpose of the following statement?*

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

11. **What is the primary purpose of the `get` method in the `HttpURLConnection` class?**

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

© 2013 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

Page 1 of 1

1

same ratio of dosing frequency of the reference drug and the test drug as in the clinical situation. Repeated ocular administration of difluprednate resulted in adverse findings including significant alteration in organ weights and histopathological changes in organs like liver and thymus accompanied by clinical pathology changes in the study. The systemic NOAEL was not obtained. However, based on minimal/less incidence of local effect, the local (ocular) NOAEL was obtained at [REDACTED] of [REDACTED]. No marked drug accumulation in systemic exposure was observed following repeated dosing for 30 days. No significant difference was observed in the toxicokinetic profiles of [REDACTED]. [REDACTED]. [REDACTED]. [REDACTED].

2.2 Summary of the Known and Potential Risks and Benefits to Human Subjects

Difluprednate was approved in US as Durezol® in 2008 in the form of difluprednate ophthalmic emulsion 0.05%. Difluprednate is used for the treatment of inflammation and pain associated with ocular surgery.

Class warnings for corticosteroids such as difluprednate are well known and state that prolonged use may result in glaucoma with damage of optic nerve, defect in visual acuity and field of vision, posterior subcapsular cataract formation. It is recommended that if corticosteroids are used for 10 days or longer, IOP should be routinely monitored. Prolonged use may also suppress the host response and thus increase the hazard of secondary ocular infections. Use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. In diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. Use of difluprednate is also contraindicated in epithelial herpes simplex, and other viral diseases of the cornea and conjunctiva and fungal disease of ocular structures.

According to Durezol package insert, ocular adverse reactions occurring in 5-15% of subjects in clinical studies with Durezol included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis. Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.

2.3 Summary of Clinical Data

There have been no specific clinical studies conducted with SPARC's [REDACTED]

2.4 Compliance Statement for Study Conduct in Accordance with Protocol, GCP and Applicable Regulatory Requirements

The study protocol, amendments to the protocol (if applicable), IB, subject recruitment procedures (e.g. advertisements) and the subject's information and informed consent form and assent forms(as applicable) as well as consent and assent (as applicable) form updates (if applicable) will be submitted to the IRB, which is constituted according to local law to obtain approval before initiation of the study and as applicable thereafter.

The study will only be initiated after receipt of the approval from the IRB. The investigator will report promptly to the IRB new information that may adversely affect the safety of the subjects or the conduct of the study.

The investigator will carry out the protocol in conformity with Good Clinical Practice (GCP) described in Guideline E6 of the ICH and applicable regulatory requirements. Before admission into the study, the written informed consent form and assent form(as applicable) must be personally signed and dated by the subject and /or guardian and by the investigator or designee who conducted the informed consent discussion.

In obtaining and documenting informed consent and assent (as applicable) the investigator must comply with the applicable regulatory requirement(s), and must adhere to GCP. The investigator must inform the subject of all pertinent aspects of the study including the written information approved/favorably assessed by the IRB.

3.0 STUDY OBJECTIVES

To evaluate the efficacy and safety of topical administration of [REDACTED] compared with [REDACTED] dose in the [REDACTED] surgery followed by [REDACTED].

4.0 OVERALL STUDY DESIGN

This study is a phase 3, randomized, multicenter, double-masked, vehicle-controlled, parallel-group clinical study. Subjects of all ages scheduled to undergo uncomplicated unilateral cataract surgery and

who meet all study entry criteria will be enrolled. ■

Prior to enrollment, the study will be discussed with prospective subjects and/or LAR/parent/gaurdian and those who are willing to enter the study will be asked to give written informed consent.

Once informed consent and assent (as applicable) has been obtained, the subjects and/or LAR/parent/gaurdian will be questioned regarding their medical history to determine whether or not they are in satisfactory health to enter the study and to determine if they meet the specific entry criteria.

4.1 Measures taken to avoid bias

4.1.1 Subject number

A large block of text has been completely redacted with a solid black rectangle.

4.1.2

[REDACTED]

[REDACTED]

4.1.3

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED].

[REDACTED] -

4.2.1 Inclusion Criteria

Inclusion criteria during the screening visit are:

1. Be male or female, of all ages

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5. Able to self-instill the IP or have a caregiver available to instill all doses of the IP, as instructed.
6. Females of childbearing potential must not be pregnant (as confirmed by a negative urine pregnancy test)

[REDACTED]

7. Be able and willing to follow study instructions and complete all required visits.

4.2.2 Exclusion Criteria

1. Any known allergy or hypersensitivity to difluprednate

7. An acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye.

11. Any active corneal pathology noted in the study eye.

14. Currently suffering from alcohol and/or drug abuse.

[REDACTED]	[REDACTED]

[REDACTED] to exclude subject based on clinical judgment, even if other eligibility criteria are satisfied.

[REDACTED]

4.2.4

A series of horizontal black bars of varying lengths, some with small black squares at their start. The bars are arranged vertically, with some having small black squares at their start. The lengths of the bars decrease as they move down the page.

5.0 STUDY PARAMETERS


5.1 Efficacy Measures

5.1.1 Primary Efficacy Variable(s)

The primary efficacy endpoint is the proportion of subjects with an anterior chamber cell (ACC) grade of 0 at Day 15 [REDACTED]

© 2019 Pearson Education, Inc.

113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2159
2160
2161
2162
2163
2164
2165
2166

■  [REDACTED]

Black bars indicate regions of the image that are completely black and do not contain any visible text or other content.

102

© 2019 Pearson Education, Inc. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s). Editorial review has determined that any suppressed content does not materially affect the overall learning experience. Pearson Education, Inc. reserves the right to remove additional content at any time if subsequent rights restrictions require it.

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

Digitized by srujanika@gmail.com

© 2013 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

6.1.3 Study medication labeling

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

1. **What is the primary purpose of the study?**

1

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] _____
[REDACTED] _____
[REDACTED] _____
[REDACTED] _____
[REDACTED]
[REDACTED]
[REDACTED]

6.1.4 [REDACTED]

The IP is to only be prescribed by the principal investigator or his/her delegated sub investigator(s), and is to only be used in accordance with this protocol. The IP must only be distributed to subjects properly qualified under this protocol to receive IP.

The investigator must keep an accurate accounting of the IP received from the supplier. IP accountability includes the amount of IP dispensed to the subjects, amount of IP returned by the subjects, and the amount returned or disposed upon the completion of the study.

6.1.5 **Return or Disposal of Investigational Product**

All used study drugs will be returned to the sponsor or their designee or destroyed at the study site. The return or disposal of study drug will be specified in writing.

7.0 STUDY METHODS AND PROCEDURES

7.1 Subject Entry Procedures

7.1.1 Overview

Subjects as defined by the criteria in [REDACTED], will be considered for entry into this study.

7.1.2 Informed Consent and Assent (as applicable)

Prior to a subject's participation in the study (i.e., changes in a subject's medical treatment and/or study specific procedures), the study will be discussed with the subject and/or LARparent/guardian. Subjects wishing to participate the study must give written informed consent and assent form (as applicable) using an informed consent form (ICF) and assent form(as applicable) The ICF form and the assent form must be the most recent version that has received approval/favorable review by a properly constituted Institutional Review Board.

7.2

A large grid of black bars on a white background, likely a placeholder or a redacted section of a document. The grid consists of approximately 20 horizontal rows and 20 vertical columns, creating a dense pattern of black rectangles. The bars are of varying lengths, with some being full-width and others being narrower. There are also a few small, isolated black bars scattered within the grid.

A series of horizontal black bars of varying lengths, likely representing a barcode or a series of data markers. The bars are arranged vertically and are of different widths, creating a pattern of varying lengths.

A horizontal bar chart with 1000 black bars. The x-axis represents the count of samples, ranging from 0 to 1000. The y-axis represents the category index, ranging from 0 to 99. The bars are arranged in two main groups: a top group of 50 categories and a bottom group of 50 categories. The top group has a higher density of bars, with many reaching the maximum value of 1000. The bottom group has a lower density, with most bars having a value of 1 or 2. The distribution is highly skewed, with a few categories having a very high number of samples and many categories having none or very few.

A horizontal bar chart with 1000 black bars. The x-axis represents the number of samples (0 to 1000) and the y-axis represents the category index (0 to 99). The bars are arranged in two main groups: a top group of 50 bars and a bottom group of 50 bars. The top group has a maximum value of approximately 950 at index 10. The bottom group has a maximum value of approximately 950 at index 99. The bars are of varying lengths, representing the count of samples for each category.

A horizontal bar chart illustrating the distribution of 1000 samples across 10 categories. The categories are indicated by vertical dashed lines on the left, and the samples are represented by black horizontal bars. The distribution is highly right-skewed, with the top 5 categories (labeled 1, 2, 3, 4, 5) containing 75% of the samples.

Category	Approximate Sample Range	Approximate Sample Count
1	100 - 150	150
2	150 - 200	180
3	200 - 250	180
4	250 - 300	180
5	300 - 350	180
6	350 - 400	100
7	400 - 450	50
8	450 - 500	50
9	500 - 550	50
10	550 - 600	50

7.3.1.7 Unscheduled Visits

Additional exams may be scheduled as necessary to ensure the safety and well-being of subjects who experience adverse effects during the course of the study. Any additional examinations during the study will be fully documented in the source documents and on Unscheduled Visit eCRFs.

7.4 Compliance with Protocol

Site personal shall contact subjects/ caregivers at least once between the visits during the treatment period via phone or email and remind them to instill IP and to complete the pain and dosing diary. A call log has to be completed by study personnel after the call.

The specifications of the log will include

1. Date & Time of call
2. Site Staff able to make contact (Y/N)
3. If Yes, Point of Contact
4. A very short description of call

Subjects who are inappropriately enrolled will be discontinued from the study. The reason for such discontinuation will be recorded as "protocol violation" in the source document and on the appropriate

page in the eCRF. Notification of such protocol violations will be sent to IRB. Subjects will be provided with a pain and dosing diary to document their assigned dosing regimen. Subject compliance with dosing will be assured by in-office review of the pain and dosing diary.

7.5 Study Duration

A horizontal bar chart consisting of seven black bars of varying lengths. The bars are positioned from left to right, with their lengths decreasing sequentially. The first bar is the longest, followed by a shorter bar, then a medium-length bar, another medium-length bar, a slightly shorter bar, a very short bar, and finally the longest bar again on the far right.

7.6 Monitoring and Quality Assurance

During the course of the study CRO monitor, or designee, will make routine site visits to review protocol compliance, assess study drug accountability, and ensure the study is being conducted according to the pertinent regulatory requirements. The review of the subjects' medical records will be performed in a manner that adequately maintains subject confidentiality. Further details of the study monitoring will be outlined in a monitoring plan.

Regulatory authorities of domestic and foreign agencies, quality assurance and or its designees may carry out on-site inspections and/or audits which may include source data checks. Therefore direct access to the original source data will be required for inspections and/or audits. All inspections and audits will be carried out giving consideration to data protection as well as subject confidentiality to the extent that local, state, and federal laws apply.

8.0

A series of horizontal black bars of varying lengths, likely representing data points or bars in a chart. The bars are positioned in a grid-like structure, with the top bar being the shortest and the bottom bar being the longest. The bars are separated by small gaps.

8.1.1 Definitions

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11. **What is the primary purpose of the *Journal of Clinical Oncology*?**

© 2019 Pearson Education, Inc.

www.english-test.net

1

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]

Relationship to study drug, to be [REDACTED]

TERM	DEFINITION	CLARIFICATION

[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]

Assessment of Expectedness

The most recent version of IB for [REDACTED] will be used for assessing the expectedness of SAE for the subjects who have received [REDACTED]

Definition of the adverse event reporting period

The AE/ SAE reporting period for safety surveillance begins when the subject signs ICF and/or assent form continues till end of study visit or early termination visit.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

© 2013 Pearson Education, Inc.

© 2019 Pearson Education, Inc.

1000

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

© 2019 Pearson Education, Inc.

© 2013 Pearson Education, Inc.

© 2013 Pearson Education, Inc.

1000 JOURNAL OF CLIMATE

© 2019 Pearson Education, Inc.

© 2010 Pearson Education, Inc. All Rights Reserved. May not be reproduced, in whole or in part, without permission of the publisher.

1

© 2019 Pearson Education, Inc.

© 2013 Pearson Education, Inc.

Topic	Percentage
The Internet	98
Smartphones	98
Cloud Computing	70
Big Data	98
Machine Learning	98
Artificial Intelligence	98
Blockchain	98
Quantum Computing	50
The Internet	98
Smartphones	98
Cloud Computing	70
Big Data	98
Machine Learning	98
Artificial Intelligence	98
Blockchain	98
Quantum Computing	50

8.3 Procedures for Reporting Serious Adverse Events (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR)

Serious Adverse Events

All SAEs must be reported according to ICH GCP or local regulations, applying the regulation with the stricter requirements. The report will contain as much available information concerning the SAE to enable the Sponsor's safety physician/ CRO to file a report, which satisfies regulatory reporting requirements.

The SAE report will be notified by Investigator within 24-hours of his/ her awareness to the Sponsor's safety physician/CRO. These timelines apply to initial reports of SAEs and to all follow-up reports.

All AEs/SAEs will be recorded on the AE Report Form and SAE report form in the eCRF and source documents.

The following minimum information must be included in the SAE form:

- Name, address and telephone number of the reporting Investigator
- IP details
- Subject identification number, initials, sex and date of birth
- Description of the SAE, measures taken and outcome

In the case of fatal or life-threatening events, please also immediately telephone the Sponsor's safety physician/CRO.

Additional follow-up information should be completed on an SAE follow-up form with a copy sent to the Sponsor's safety physician/CRO.

In exceptional circumstances, an SAE (or follow-up information) may be reported by telephone. In these cases, a written report must be sent immediately thereafter by e-mail to the Sponsor's safety physician/CRO.

Relevant pages from the eCRF may be provided in parallel (e.g., medical history, concomitant drugs). Additional documents may be provided by the Investigator, if available (e.g., laboratory results, hospital report, autopsy report). In all cases, the information provided on the SAE Report Form must be consistent with the data about the event recorded in the eCRF.

The Investigator must respond to any request for follow-up information (e.g., additional information, outcome, final evaluation, other records where needed) or to any question the Sponsor's safety physician/CRO may have on the AE. This is necessary to ensure prompt assessment of the event by the Sponsor's safety physician to allow the Sponsor to meet strict regulatory timelines associated with expedited safety reporting obligations.

Requests for follow-up will usually be made via the responsible Sponsor's safety physician/CRO.

Suspected Unexpected Serious Adverse Reactions (SUSARs):

The applicable Regulatory Authorities shall be initially notified by Sponsor Safety Physician/ CRO of any SUSAR, no later than 15 calendar days from the "date learned" of the event. The applicable Regulatory Authorities will be initially notified as per regulation within 7 calendar days of any fatal or life-threatening SUSAR. If the safety report submitted within 7 calendar days is complete, an additional submission within 15 days from day 0 is not required.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8.4

8.5 Follow-Up

The Investigator should take all appropriate measures to ensure the safety of the subjects, including referral to a specialist if indicated. The Investigator should follow up on the outcome of any AE till end of study visit/ early termination visit. All SAEs will be followed until the event has resolved or stabilized as per medical judgement of the investigator.

Any AE/ SAE brought to the attention of the Investigator post end of study visit/ early termination visit requires notification to Sponsor and other stakeholders if it is considered related to study drug.

Any AE unresolved at the time of end of study/ early termination visit requires detailed evaluation and will be followed for outcome as per medical judgment of the investigator.

8.6 PREGNANCY

A pregnancy test will be performed at screening and at visits specified in the protocol. Females of childbearing potential must not be pregnant or lactating (as confirmed by a negative urine pregnancy test).

A series of 12 horizontal black bars of varying lengths, decreasing from left to right. The bars are evenly spaced and extend from the left edge of the frame to different points on the right, creating a visual effect of decreasing magnitude or value.

9.0 STATISTICAL HYPOTHESES AND METHODS OF ANALYSES

9.1.1 Primary Efficacy Endpoint

The primary efficacy endpoint is the proportion of subjects with an ACC grade of 0 at Day 15.

For more information, contact the Office of the Vice President for Research and the Office of the Vice President for Student Affairs.


9.1.2 Key Secondary Efficacy Endpoint

The key secondary efficacy endpoint is the proportion of subjects who achieve a pain score of 0

at Day 15

9.1.3

9.1.4 Analysis Populations




9.1.5 Baseline Variables


Age in years (7 to < 65, \geq 65)

- Sex (male, female)
- Ethnicity (hispanic, nonhispanic)
- Race (white, black, other)

9.2



[Redacted]								
[Redacted]								
[Redacted]								
[Redacted]								
[Redacted]								



A horizontal row of nine small black rectangles, each representing a 1x1 pixel in a 3x3 kernel. The rectangles are evenly spaced and aligned horizontally.

Topic	Percentage
Smart homes	98
Smart cities	98
Smart transportation	98
Smart energy	98
Smart waste management	98
Smart agriculture	98
Smart healthcare	98
Smart water management	98
Smart manufacturing	98
Smart retail	98
Smart government services	98
The concept of a 'smart city'	60

██████████	██████████	████	████	████	████	████	██████████	████████████████
██████████	██████████							██████████
████	██████████	████	████	████	██████████	██████████	██████████	████
████	██████████	████	████	████	██████████	██████████	██████████	████

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9.3 Methods of Analysis

9.3.1 General Approach

The final analysis will be conducted when all subjects have either completed the [REDACTED] visit or have otherwise [REDACTED]. At that time, the database will be cleaned, processed, and locked. At this stage the study will be unblinded. Efficacy and safety endpoints will be analyzed based on this locked database.

Summary statistics for categorical variables will include frequency and percentage. For continuous variables, number of subjects with non-missing value (n), mean, median, standard deviation (SD), minimum (min), and maximum (max) will be reported.

Subject disposition, demographics and baseline characteristics will be summarized [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

All summaries and analyses will be presented by treatment group.

Any deviations from the original statistical plan will be described in the final report.

9.3.2 Efficacy Analysis

9.3.2.1 Analysis of Primary Efficacy Endpoint

The primary efficacy endpoint is the proportion of subjects with an ACC grade of 0 at Day 15.

[REDACTED]
[REDACTED] model.

9.3.3 [REDACTED]

9.3.3.1.1 [REDACTED]

9.3.3.1.2 Incidence of TEAEs

A summary of TEAEs will be presented by SOC and PT by treatment group. If a subject reports the same PT multiple times, then [REDACTED] As with the PT, if a subject reports multiple AEs within the same SOC, [REDACTED]

9.3.3.1.3 Severity of TEAEs

A summary of TEAEs by SOC, PT, and severity will be presented by treatment group. Severity will be graded by the investigator as “Mild,” “Moderate,” or “Severe.” [REDACTED]

9.3.3.1.4 Relationship of Treatment-Emergent Adverse Events to the IP

A summary of TEAEs by SOC, PT, and relationship to the IP will be presented by treatment group. The relationships indicate the investigator's assessment of whether or not the event was caused by the IP. The possible relationships are "Not Related," "Possibly Related," and "Related." [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9.3.3.1.5 Serious Adverse Events

Serious adverse events (SAEs) will be listed by subject; SAEs will be summarized by event and treatment group.

9.3.3.1.6 Adverse Events Leading to Study Drug Withdrawal

All AEs leading to study withdrawal or study drug withdrawal will be listed and may be summarized if appropriate.

9.3.3.2 [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9.3.3.2.2 [REDACTED]

9.3.3.2.3 [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

9.3.3.2.4 [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]
[REDACTED]

9.3.4 Concomitant Medications

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

Term	Percentage
GMOs	85
Organic	80
Natural	75
Artificial	65
Organic	82
Natural	78
Artificial	68
Organic	83
Natural	79
Artificial	67
Organic	81
Natural	77
Artificial	66
Organic	84
Natural	80
Artificial	69
Organic	86
Natural	81
Artificial	70
Organic	87
Natural	82
Artificial	71
Organic	88
Natural	83
Artificial	72
Organic	89
Natural	84
Artificial	73
Organic	90
Natural	85
Artificial	74
Organic	91
Natural	86
Artificial	75
Organic	92
Natural	87
Artificial	76
Organic	93
Natural	88
Artificial	77
Organic	94
Natural	89
Artificial	78
Organic	95
Natural	90
Artificial	79
Organic	96
Natural	91
Artificial	80
Organic	97
Natural	92
Artificial	81
Organic	98
Natural	93
Artificial	82
Organic	99
Natural	94
Artificial	83
Organic	100
Natural	95
Artificial	84

10.0 COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL CONSIDERATIONS AND ADMINISTRATIVE ISSUES

This study will be conducted in compliance with the protocol, current Good Clinical Practices, including the International Conference on Harmonization (ICH) Guidelines, and in general, consistent with the Declaration of Helsinki. In addition, all applicable local, state, and federal requirements relevant to the use of IPs in the countries involved will be adhered to.

10.1 Protection of Human Subjects

10.1.1 Subject Informed Consent and Assent(as applicable)

Informed consent and assent (as applicable) must take place before any study specific procedures are initiated. Signed and dated written informed consent and assent(as applicable) must be obtained from each subject prior to enrollment into the study.

All informed consent forms and assent forms(as applicable) must be approved for use by the sponsor and receive approval/favorable opinion from an IRB/IEC prior to their use. If the consent form and

assent form requires revision (eg, due to a protocol

amendment or significant new safety information), it is the investigator's responsibility to ensure that the amended informed consent form and assent form(as applicable) is reviewed and approved by CRO prior to submission to the governing IRB/IEC and that it is read, signed and dated by all subjects subsequently enrolled in the study as well as those currently enrolled in the study.

If informed consent and assent (as applicable) is taken under special circumstances (oral informed consent), then the procedures to be followed must be determined by CRO and/or study sponsor and provided in writing by CRO and/or study sponsor prior to the consent process.

10.1.2 Institutional Review Board Approval

This study is to be conducted in accordance with Institutional Review Board regulations.

Only current IRB/ERC approved version of the ICF/Accent form will be used.

10.2 Ethical Conduct of the Study

This study will be conducted in accordance with the ethical principles that originated with the Declaration of Helsinki.

10.3 Subject Confidentiality

All personal study subject data collected and processed for the purposes of this study should be maintained by the investigator and his/her staff with adequate precautions as to ensure that the confidentiality of the data in accordance with local, state, and federal laws and regulations.

Monitors, auditors and other authorized representatives of CRO, the sponsor, the IRB/IEC approving this study, the Food and Drug Administration (FDA), the Department of Health and Human Services, other domestic government agencies, and other foreign regulatory agencies will be granted direct access to the study subject's original medical and study records for verification of the data and/or clinical trial procedures. Access to this information will be permitted to the aforementioned individuals to the extent permitted by law.

A report of the results of this study may be published or sent to the appropriate health authorities in any country in which the IP may ultimately be marketed, but the subject's identity will not be disclosed in these documents.

10.4 Documentation

Source documents may include a subject's medical records, hospital charts, clinic charts, the investigator's study subject files, as well as the results of diagnostic tests performed. The investigator's copy of the electronic case report forms (eCRFs) serves as the investigator's record of a subject's study-related data.

10.4.1 Retention of Documentation

All study related correspondence, subject records, consent forms, record of the distribution and use of all IPs and copies of eCRFs should be maintained on file for at least two years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region; or until at least two years have elapsed since the formal discontinuation of clinical development of the IP. These documents will be retained for a longer period if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to be retained.

If the responsible investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping study records, custody must be transferred to a person who will accept the responsibility. The sponsor must be notified in writing of the name and address of the new custodian.

10.5 Recording of Data on Source Documents and Electronic Case Reports Forms (eCRFs)

The investigator is responsible for ensuring that study data is completely and accurately recorded on each subject's eCRF, source document, and all study-related material. All study data should also be attributable, legible, contemporaneous, and original. Prior to the start of the study a signature and delegation list will be completed showing the signatures and hand written initials of all who are authorized to entry data or make corrections in the documents. Recorded datum should only be corrected in a manner that does not obliterate, destroy, or render illegible the previous entry (eg, by drawing a single line through the incorrect entry and writing the revision next to the corrected data). An individual who has corrected a data entry should make clear who made the correction when and why along with justification, by adding to the correction his/her initials as well as the date of the correction.

10.6 Handling of Biological Specimens

10.7 Publications

Authorship and manuscript composition will reflect cooperation among all parties involved in the study. Authorship will be established before writing the manuscript. The study sponsor will have the final decision regarding the manuscript and publication.

11.0 REFERENCES

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

12.2 Examination Procedures, Tests, Equipment, and Techniques

Urine Pregnancy Tests (If Applicable)

Standard dipstick-based urine pregnancy tests will be administered to subjects that are of child bearing potential to assess pregnancy status as outlined in the [REDACTED]. Child bearing potential is defined as any female who has had her first menses, not had a hysterectomy or bilateral tubal ligation, and has not been post-menopausal for at least 12 consecutive months. Pregnancy is not to be considered an AE, but it is an important medical event that must be followed up as described in [REDACTED]

Blood Pressure (mmHg)

Systolic and diastolic blood pressure should be measured in the same arm each time using a sphygmomanometer with the subjects who have been in a resting state (seated upright) at least 5 minutes. Blood pressure will be recorded in mm Hg.

[REDACTED] must be assessed using an [REDACTED]
[REDACTED] chart and as indicated in the study flowchart in [REDACTED]. The procedure used will be consistent with the recommendations provided for using the [REDACTED]. [REDACTED] should be evaluated at the [REDACTED] in the study (ie, [REDACTED]). [REDACTED] testing should be done with [REDACTED] correction.

A [REDACTED] will be considered [REDACTED] significant, and may indicate an [REDACTED]

Equipment


If smaller reproduction eg, from Prevent Blindness) wall charts are used, the subject viewing distance should be (or as specified by the manufacturer). In ALL cases, for purposes of standardizing the testing conditions during the study, all sites must use only the 'R' charts, and the right eye should be tested first. For reflectance (wall) charts, the chart should be placed frontally and well-illuminated.

The chart should be at a comfortable viewing angle. The right eye should be tested first. The subject should attempt to read each letter, line-by-line, left to right, beginning with line 1 at the top of the chart. The subject should be told that the chart has letters only, no numbers. If the subject reads a number, he or she should be reminded that the chart contains no numbers, and the examiner should then request a letter in lieu of the number. The subject should be asked to read slowly, so as to achieve the best identification of each letter. He/she is not to proceed to the next letter until he/she has given a definite response.



If the subject changes a response (eg, 'that was a "C" not an "O"') before he has read aloud the next letter, then the change must be accepted. If the subject changes a response having read the next letter, then the change is not to be accepted. The examiner should never point to the chart or to specific letters on the chart during the test.

A maximum effort should be made to identify each letter on the chart. When the subject says he or she cannot read a letter, he or she should be encouraged to guess. If the subject identifies a letter as one of two letters, he or she should be asked to choose one letter and, if necessary, to guess. When it becomes evident that no further meaningful readings can be made, despite encouragement to read or guess, the examiner should stop the test for that eye. However, all letters on the last line should be attempted as letter difficulties vary and the last may be the only one read correctly. The number of letters missed or read incorrectly should be noted.

For Example: Subject correctly reads 4 of 5 letters on the 0.2 line, and 2 of 5 letters on the 0.1 line.



In order to provide standardized and well-controlled assessments of visual acuity during the study, all visual acuity assessments at a single site must be consistently done using the same lighting conditions and same correction if possible during the entire study. If the same correction cannot be used (ie, a subject forgets his glasses), the reason for the change in correction should be documented.



[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]


[REDACTED]

The investigator or study staff will also be asked to record the time these 2 measurements were obtained.



In addition to the [REDACTED], subjects will be asked to assess their pain via a diary at home [REDACTED] to each dose, and for [REDACTED] after the [REDACTED] dose, until the [REDACTED]

For this the following pain assessment criteria where [REDACTED].



In addition to the above, dosing information shall be completed by the patient/caregiver in the pain and dosing diary along with any information related to the adverse events noted. Detailed diary completion instructions will be provided to all subjects. If necessary, a caregiver may transcribe the subject's pain assessment on to the diary for subjects who are unable to write. In this case, study staff must review the diary with the subject and ensure the subject agrees with the recorded information

[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]
------------	------------

[REDACTED]

[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

© 2013 Pearson Education, Inc. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s). Editorial review has determined that any suppressed content does not materially affect the overall learning experience. Pearson Education, Inc. reserves the right to remove additional content at any time if subsequent rights restrictions require it.

Digitized by srujanika@gmail.com

© 2013 Pearson Education, Inc.

© 2013 Pearson Education, Inc.

113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2159
2160
2161
2162
2163
2164
2165
2166

—

—

—

12.3 Protocol Amendment Summary

■ XXXXXXXXXX

■ [REDACTED] ■ [REDACTED] ■ [REDACTED]
■ [REDACTED] ■ [REDACTED] ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2444 or research@uiowa.edu.

1000

1

12.4 Investigator's Signature

Protocol Title:

A Randomized, Double-Masked, Parallel Group, Multicenter, Study
To Evaluate Efficacy And Safety of SPARC's SDN -037 Twice
Daily Compared With Vehicle For The Treatment Of Inflammation
And Pain Associated With Ocular Surgery.


Protocol Number: CLR_16_31

Version No. Date 01

Amendment No. Date 02, 02 Aug 2019

I agree to implement and conduct the study diligently and in strict compliance with the protocol, good clinical practices and all applicable laws and regulations. I agree to maintain all information supplied by CRO and the sponsor in confidence and, when this information is submitted to an Institutional Review Board (IRB), Ethical Review Committee (ERC) or another group, it will be submitted with a designation that the material is confidential.

I have read this protocol in its entirety, including the above statement, and I agree to all aspects.

A large rectangular area of the page has been completely blacked out, likely to redact sensitive information such as a signature or a large block of text.A small, narrow horizontal blacked-out area is located near the bottom left of the page.A small, narrow horizontal blacked-out area is located near the bottom center of the page.A small, narrow horizontal blacked-out area is located near the bottom right of the page.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use

Initial U.S. Approval: 2008

INDICATIONS AND USAGE

DUREZOL® is a topical corticosteroid that is indicated for:

- The treatment of inflammation and pain associated with ocular surgery (1.1)
- The treatment of endogenous anterior uveitis (1.2)

DOSAGE AND ADMINISTRATION

- For the treatment of inflammation and pain associated with ocular surgery instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response. (2.1)
- For the treatment of endogenous anterior uveitis, instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated. (2.2)

DOSAGE FORMS AND STRENGTHS

DUREZOL contains 0.05% difluprednate, as a sterile preserved ophthalmic emulsion for topical ophthalmic use only. (3)

CONTRAINDICATIONS

DUREZOL, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. (4)

WARNINGS AND PRECAUTIONS

- **Intraocular pressure (IOP) increase:** Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored. (5.1)
- **Cataracts:** Use of corticosteroids may result in posterior subcapsular cataract formation. (5.2)
- **Delayed healing:** The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. (5.3)
- **Bacterial infections:** Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. (5.4)
- **Viral infections:** Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). (5.5)
- **Fungal infections:** Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. (5.6)

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2017

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.1 Ocular Surgery

1.2 Endogenous Anterior Uveitis

2 DOSAGE AND ADMINISTRATION

2.1 Ocular Surgery

2.2 Endogenous Anterior Uveitis

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Intraocular pressure (IOP) Increase

5.2 Cataracts

5.3 Delayed Healing

5.4 Bacterial Infections

5.5 Viral Infections

5.6 Fungal Infections

5.7 Topical Ophthalmic Use Only

5.8 Contact Lens Wear

6 ADVERSE REACTIONS

6.1 Ocular Surgery

6.2 Endogenous Anterior Uveitis

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Teratogenic Effects

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

14.1 Ocular Surgery

14.2 Endogenous Anterior Uveitis

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Ocular Surgery

DUREZOL® (diluprednate ophthalmic emulsion) 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery.

1.2 Endogenous Anterior Uveitis

DUREZOL is also indicated for the treatment of endogenous anterior uveitis.

2 DOSAGE AND ADMINISTRATION

2.1 Ocular Surgery

Instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.

2.2 Endogenous Anterior Uveitis

Instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.

3 DOSAGE FORMS AND STRENGTHS

DUREZOL contains 0.05% diluprednate as a sterile preserved emulsion for topical ophthalmic administration.

4 CONTRAINDICATIONS

The use of DUREZOL, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.

5 WARNINGS AND PRECAUTIONS

5.1 Intraocular pressure (IOP) Increase

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored.

5.2 Cataracts

Use of corticosteroids may result in posterior subcapsular cataract formation.

5.3 Delayed Healing

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

5.4 Bacterial Infections

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.

5.5 Viral Infections

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

5.6 Fungal Infections

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

5.7 Topical Ophthalmic Use Only

DUREZOL is not indicated for intraocular administration.

5.8 Contact Lens Wear

DUREZOL should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of DUREZOL. The preservative in DUREZOL may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of DUREZOL.

6 ADVERSE REACTIONS

The following serious reactions are found elsewhere in the labeling:

- Elevated IOP [*see Warnings and Precautions (5.1)*]
- Posterior subcapsular cataract formation [*see Warnings and Precautions (5.2)*]
- Secondary ocular infection [*see Warnings and Precautions (5.4)*]
- Perforation of the globe [*see Warnings and Precautions (5.3)*]

6.1 Ocular Surgery

Ocular adverse reactions occurring in 5% to 15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1% to 5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis. Ocular adverse reactions occurring in less than 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis. Most of these reactions may have been the consequence of the surgical procedure.

6.2 Endogenous Anterior Uveitis

A total of 200 subjects participated in the clinical trials for endogenous anterior uveitis, of which 106 were exposed to DUREZOL. The most common adverse reactions of those exposed to DUREZOL occurring in 5% to 10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis. Adverse reactions occurring in 2% to 5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Teratogenic Effects

Pregnancy Category C

Difluprednate has been shown to be embryotoxic (decrease in embryonic body weight and a delay in embryonic ossification) and teratogenic (cleft palate and skeletal anomalies) when administered subcutaneously to rabbits during organogenesis at a dose of 1-10 mcg/kg/day. The no-observed-effect-level (NOEL) for these effects was 1 mcg/kg/day, and 10 mcg/kg/day was considered to be a teratogenic dose that was concurrently found in the toxic dose range for fetuses and pregnant females. Treatment of rats with 10 mcg/kg/day subcutaneously during organogenesis did not result in any reproductive toxicity, nor was it maternally toxic. At 100 mcg/kg/day after subcutaneous administration in rats, there was a decrease in fetal weights and delay in ossification, and effects on weight gain in the pregnant females. It is difficult to extrapolate these doses of difluprednate to maximum daily human doses of DUREZOL, since DUREZOL is administered topically with minimal systemic absorption, and difluprednate blood levels were not measured in the reproductive animal studies. However, since use of difluprednate during human pregnancy has not been evaluated and cannot rule out the possibility of harm, DUREZOL should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus.

8.3 Nursing Mothers

It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when DUREZOL is administered to a nursing woman.

8.4 Pediatric Use


DUREZOL was evaluated in a 3-month, multicenter, double-masked trial in 79 pediatric patients (39 DUREZOL; 40 prednisolone acetate) 0 to 3 years of age for the treatment of inflammation following cataract surgery. A similar safety profile was observed in pediatric patients comparing DUREZOL to prednisolone acetate ophthalmic suspension, 1%.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

11 DESCRIPTION

DUREZOL (difluprednate ophthalmic emulsion) 0.05% is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. The chemical name is $6\alpha,9$ -difluoro- $11\beta,17,21$ -trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-butyrate (CAS number 23674-86-4). Difluprednate is represented by the following structural formula:



Difluprednate has a molecular weight of 508.56, and the empirical formula is $C_{27}H_{34}F_2O_7$.

Each mL of DUREZOL contains: **ACTIVE:** difluprednate 0.5 mg (0.05%); **INACTIVE:** boric acid, castor oil, glycerin, polysorbate 80, water for injection, sodium acetate, edetate disodium, sodium hydroxide (to adjust the pH to 5.2 to 5.8). The emulsion is essentially isotonic with a tonicity of 304 to 411 mOsm/kg. **PRESERVATIVE:** sorbic acid 0.1%.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Difluprednate is structurally similar to other corticosteroids.

12.4.1 12.3 Pharmacokinetics

Difluprednate undergoes deacetylation in vivo to 6α , 9-difluoroprednisolone 17-butyrate (DFB), an active metabolite of difluprednate.

Clinical pharmacokinetic studies of difluprednate after repeat ocular instillation of 2 drops of difluprednate (0.01% or 0.05%) four times per day for 7 days showed that DFB levels in blood were below the quantification limit (50 ng/mL) at

all time points for all subjects, indicating the systemic absorption of difluprednate after ocular instillation of DUREZOL is limited.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

Difluprednate was not genotoxic in vitro in the Ames test, and in cultured mammalian cells CHL/IU (a fibroblastic cell line derived from the lungs of newborn female Chinese hamsters). An in vivo micronucleus test of difluprednate in mice was also negative. Treatment of male and female rats with subcutaneous difluprednate up to 10 mcg/kg/day prior to and during mating did not impair fertility in either gender. Long-term studies have not been conducted to evaluate the carcinogenic potential of difluprednate.

13.2 Animal Toxicology and/or Pharmacology

In multiple studies performed in rodents and non-rodents, subchronic and chronic toxicity tests of difluprednate showed systemic effects such as suppression of body weight gain; a decrease in lymphocyte count; atrophy of the lymphatic glands and adrenal gland; and for local effects, thinning of the skin; all of which were due to the pharmacologic action of the molecule and are well known glucocorticosteroid effects. Most, if not all of these effects were reversible after drug withdrawal. The NOEL for the subchronic and chronic toxicity tests were consistent between species and ranged from 1-1.25 mcg/kg/day.

14 CLINICAL STUDIES

14.1 Ocular Surgery

Clinical efficacy was evaluated in 2 randomized, double-masked, placebo-controlled trials in which subjects with an anterior chamber cell grade greater than or equal to "2" (a cell count of 11 or higher) after cataract surgery were assigned to DUREZOL or placebo (vehicle) following surgery. One drop of DUREZOL or vehicle was self-instilled either 2 times per day or 4 times per day for 14 days, beginning the day after surgery. The presence of complete clearing (a cell count of 0) was assessed 3, 8 and 15 days post surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies, a significant benefit was seen in the 4 times per day DUREZOL-treated group in ocular inflammation, at Days 8 and 15, and reduction of pain, at Days 3, 8 and 15, when compared with placebo. The consolidated clinical trial results are provided below.

Figure 1 Percent of Subjects With Anterior Chamber Cells Clearing (Cell Count = 0)





Figure 2 Percent of Subjects Who Were Pain Free



14.2 Endogenous Anterior Uveitis

Clinical efficacy was evaluated in two randomized, double masked active controlled trials in which patients who presented with endogenous anterior uveitis were treated with either DUREZOL 4 times daily or prednisolone acetate ophthalmic suspension, 1%, 8 times daily for 14 days. Both studies demonstrated that DUREZOL was equally effective as prednisolone acetate ophthalmic suspension, 1% in treating subjects with endogenous anterior uveitis. The results are found in Table 1 below.

12.4.2 Table 1: Mean Change from Baseline in Anterior Chamber Cell Grade*

Study 1 time point	DUREZOL N=57	Prednisolone Acetate N=53	Difference [†] (95% CI)
Baseline	2.6	2.5	0.0 (-0.22, 0.28)
Day 3	-1.0	-1.0	-0.1 (-0.35, 0.25)
Day 7	-1.6	-1.5	-0.0 (-0.31, 0.25)
Day 14	-2.0	-1.8	-0.2 (-0.46, 0.10)
Day 21	-2.2	-1.9	-0.3 (-0.53, 0.01)
Day 28	-2.2	-2.1	-0.1 (-0.37, 0.18)
Day 35	-2.1	-2.0	-0.1 (-0.39, 0.20)
Day 42	-2.1	-2.1	0.0 (-0.27, 0.34)
Study 2 time point	DUREZOL N=50	Prednisolone Acetate N=40	Difference [†] (95% CI)
Baseline	2.4	2.4	0.0 (-0.21, 0.29)
Day 3	-0.9	-0.9	-0.0 (-0.34, 0.25)
Day 7	-1.7	-1.6	-0.1 (-0.35, 0.21)

Day 14	-1.9	-1.8	-0.1 (-0.34, 0.20)
Day 21	-2.0	-2.0	0.0 (-0.25, 0.28)
Day 28	-2.0	-2.0	0.0 (-0.21, 0.26)
Day 35	-2.1	-2.0	-0.1 (-0.32, 0.16)
Day 42	-2.0	-1.9	-0.1 (-0.36, 0.24)

*with 5 grades: 0 = 0 cells; 1 = 1 to 10 cells; 2 = 11 to 20 cells; 3 = 21 to 50 cells; and 4 = greater than 50 cells

[†]adjusted for baseline AC cell grade and study center and based on ITT dataset with LOCF for missing data

CI = confidence interval

16 HOW SUPPLIED/STORAGE AND HANDLING

DUREZOL (difluprednate ophthalmic emulsion) 0.05% is a sterile, aqueous topical ophthalmic emulsion supplied in an opaque plastic bottle with a controlled drop tip and a pink cap in the following sizes:

5 mL in a 8 mL bottle.....NDC 0065-9240-07

12.4.3 Storage and Handling

Store at 15°C to 25°C (59°F to 77°F). Do not freeze. Protect from light. When not in use, keep the bottles in the protective carton.

13.0 PATIENT COUNSELING INFORMATION

13.1 Risk of Contamination

This product is sterile when packaged. Advise patients not to allow the dropper tip to touch any surface, as this may contaminate the emulsion.

Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.

13.1.1.1 Risk of Secondary Infection

If pain develops, or if redness, itching, or inflammation becomes aggravated, advise patients to consult a physician.

13.1.1.2 Contact Lens Wear

DUREZOL should not be instilled while wearing contact lenses. Advise patients to remove contact lenses prior to instillation of DUREZOL. The preservative in DUREZOL may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of DUREZOL.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]

List of Changes



Contents:



List of Changes

sparc®

